雷莫西尤单抗用于索拉非尼治疗后甲胎蛋白升高的晚期肝细胞癌患者(REACH-2):一项随机、双盲、安慰剂对照的3期试验
REACH-2在20个国家92家中心纳入292例甲胎蛋白≥400 ng/mL、既往索拉非尼治疗后的晚期肝细胞癌患者,2:1随机接受雷莫西尤单抗8 mg/kg每2周静脉给药或安慰剂。中位随访7.6个月,雷莫西尤单抗组总生存(8.5个月 vs 7.3个月;HR 0.710,95%CI 0.531-0.949;p=0.0199)和无进展生存(2.8个月 vs 1.6个月;HR 0.452,95%CI 0.339-0.603;p<0.0001)均显著优于安慰剂组。
要点
- 甲胎蛋白≥400 ng/mL的晚期肝细胞癌患者中,雷莫西尤单抗较安慰剂显著改善总生存和无进展生存。
- 客观缓解率两组无显著差异(雷莫西尤单抗组5% vs 安慰剂组1%;p=0.1697)。
- ≥3级治疗中出现的不良事件中,高血压(13% vs 5%)、低钠血症(6% vs 0)在雷莫西尤单抗组更常见。
核心结论
- REACH-2达到主要终点,在甲胎蛋白≥400 ng/mL且既往接受索拉非尼治疗的肝细胞癌患者中,雷莫西尤单抗较安慰剂改善总生存。
- 雷莫西尤单抗耐受性良好,安全性可控。
- 据作者所知,REACH-2是首个在生物标志物选择的人群中开展的阳性3期肝细胞癌试验。
研究设计与样本
- REACH-2是一项随机、双盲、安慰剂对照的3期试验,在20个国家的92家医院、诊所和医疗中心开展。
- 纳入年龄≥18岁、组织学或细胞学确诊肝细胞癌或临床诊断肝硬化合并肝细胞癌、BCLC B或C期、Child-Pugh A级、ECOG体能状态0或1、甲胎蛋白≥400 ng/mL、既往接受过一线索拉非尼的患者。
- 通过交互式网络应答系统按2:1随机分配至雷莫西尤单抗8 mg/kg静脉给药每2周一次或安慰剂,所有患者均接受最佳支持治疗。
- 主要终点为总生存;次要终点包括无进展生存、客观缓解比例、影像学进展时间、安全性、FHSI-8评分恶化时间和ECOG体能状态恶化时间。
- 将REACH-2与REACH(NCT01140347)中甲胎蛋白≥400 ng/mL患者的个体数据进行汇总分析;有效性分析按意向治疗进行,安全性分析纳入至少接受一剂研究药物的所有患者。
主要发现
- 2015年7月26日至2017年8月30日共随机分配292例患者,雷莫西尤单抗组197例,安慰剂组95例。
- 中位随访7.6个月(IQR 4.0-12.5),雷莫西尤单抗组中位总生存8.5个月(95%CI 7.0-10.6)vs 安慰剂组7.3个月(95%CI 5.4-9.1),HR 0.710(95%CI 0.531-0.949),p=0.0199。
- 雷莫西尤单抗组中位无进展生存2.8个月(95%CI 2.8-4.1)vs 安慰剂组1.6个月(95%CI 1.5-2.7),HR 0.452(95%CI 0.339-0.603),p<0.0001。
- 客观缓解比例两组无显著差异:雷莫西尤单抗组9例(5%,共197例)vs 安慰剂组1例(1%,共95例),p=0.1697。
- FHSI-8总分恶化时间(3.7个月[95%CI 2.8-4.4] vs 2.8个月[95%CI 1.6-2.9];HR 0.799[95%CI 0.545-1.171];p=0.238)和ECOG体能状态恶化时间(HR 1.082[95%CI 0.639-1.832];p=0.77)两组无差异。
关键数值与推荐
- 入组要求甲胎蛋白浓度≥400 ng/mL。
- 雷莫西尤单抗给药方案为8 mg/kg静脉给药每2周一次。
- 两组中至少5%患者发生的≥3级治疗中出现的不良事件:高血压(雷莫西尤单抗组25例[13%] vs 安慰剂组5例[5%])、低钠血症(11例[6%] vs 0例)、天冬氨酸氨基转移酶升高(6例[3%] vs 5例[5%])。
- 任何级别和原因的严重不良事件:雷莫西尤单抗组68例(35%)vs 安慰剂组28例(29%)。
- 雷莫西尤单抗组3例患者死于经判定与研究治疗相关的治疗中出现的不良事件(分别为急性肾损伤、肝肾综合征和肾功能衰竭)。
临床怎么用
- 对于甲胎蛋白≥400 ng/mL且既往接受过索拉非尼治疗的晚期肝细胞癌患者,雷莫西尤单抗8 mg/kg每2周一次静脉给药联合最佳支持治疗可改善总生存和无进展生存。
- 治疗期间需关注高血压、低钠血症和天冬氨酸氨基转移酶升高等不良事件,以及严重不良事件和与治疗相关的死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher. METHODS: REACH-2 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 92 hospitals, clinics, and medical centres in 20 countries. Eligible patients were aged 18 years or older and had histologically or cytologically confirmed hepatocellular carcinoma, or diagnosed cirrhosis and hepatocellular carcinoma, Barcelona Clinic Liver Cancer stage B or C disease, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group (ECOG) performance statuses of 0 or 1, α-fetoprotein concentrations of 400 ng/mL or greater, and had previously received first-line sorafenib. Participants were randomly assigned (2:1) via an interactive web response system with a computer-generated random sequence to 8 mg/kg intravenous ramucirumab every 2 weeks or placebo. All patients received best supportive care. The primary endpoint was overall survival. Secondary endpoints were progression-free survival, proportion of patients achieving an objective response, time to radiographic progression, safety, time to deterioration in scores on the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 (FHSI-8), and time to deterioration in ECOG performance status. We also pooled individual patient data from REACH-2 with data from REACH (NCT01140347) for patients with α-fetoprotein concentrations of 400 ng/mL or greater. Efficacy analyses were by intention to treat, whereas safety analyses were done in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02435433. FINDINGS: Between July 26, 2015, and Aug 30, 2017, 292 patients were randomly assigned, 197 to the ramucirumab group and 95 to the placebo group. At a median follow-up of 7·6 months (IQR 4·0-12·5), median overall survival (8·5 months [95% CI 7·0-10·6] vs 7·3 months [5·4-9·1]; hazard ratio [HR] 0·710 [95% CI 0·531-0·949]; p=0·0199) and progression-free survival (2·8 months [2·8-4·1] vs 1·6 months [1·5-2·7]; 0·452 [0·339-0·603]; p<0·0001) were significantly improved in the ramucirumab group compared with the placebo group. The proportion of patients with an objective response did not differ significantly between groups (nine [5%] of 197 vs one [1%] of 95; p=0·1697). Median time to deterioration in FHSI-8 total scores (3·7 months [95% CI 2·8-4·4] vs 2·8 months [1·6-2·9]; HR 0·799 [95% CI 0·545-1·171]; p=0·238) and ECOG performance statuses (HR 1·082 [95% CI 0·639-1·832]; p=0·77) did not differ between groups. Grade 3 or worse treatment-emergent adverse events that occurred in at least 5% of patients in either group were hypertension (25 [13%] in the ramucirumab group vs five [5%] in the placebo group), hyponatraemia (11 [6%] vs 0) and increased aspartate aminotransferase (six [3%] vs five [5%]). Serious adverse events of any grade and cause occurred in 68 (35%) patients in the ramucirumab group and 28 (29%) patients in the placebo group. Three patients in the ramucirumab group died from treatment-emergent adverse events that were judged to be related to study treatment (one had acute kidney injury, one had hepatorenal syndrome, and one had renal failure). INTERPRETATION: REACH-2 met its primary endpoint, showing improved overall survival for ramucirumab compared with placebo in patients with hepatocellular carcinoma and α-fetoprotein concentrations of at least 400 ng/mL who had previously received sorafenib. Ramucirumab was well tolerated, with a manageable safety profile. To our knowledge, REACH-2 is the first positive phase 3 trial done in a biomarker-selected patient population with hepatocellular carcinoma. FUNDING: Eli Lilly.
引用
- Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019. PMID: 30665869. doi:10.1016/S1470-2045(18)30937-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。